Published in Oncogene on September 29, 2014
Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer (2015) 0.97
Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer. Int J Mol Sci (2016) 0.95
TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma. Oncotarget (2015) 0.93
Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J Transl Med (2016) 0.92
The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci (2015) 0.91
Molecular targets and pathways involved in liver metastasis of colorectal cancer. Clin Exp Metastasis (2015) 0.90
Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Oncotarget (2016) 0.81
The functions and clinical applications of tumor-derived exosomes. Oncotarget (2016) 0.81
TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer (2016) 0.79
A new mouse avatar model of non-small cell lung cancer. Front Oncol (2015) 0.78
CD44v6-competent tumor exosomes promote motility, invasion and cancer-initiating cell marker expression in pancreatic and colorectal cancer cells. Oncotarget (2016) 0.78
Exosomes as miRNA Carriers: Formation-Function-Future. Int J Mol Sci (2016) 0.76
Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene (2017) 0.75
MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers. Oncotarget (2017) 0.75
Exosomes: A Novel Strategy for Treatment and Prevention of Diseases. Front Pharmacol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol (2007) 37.10
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Cancer metastasis: building a framework. Cell (2006) 19.67
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 13.49
Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science (2002) 8.27
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell (2010) 7.20
Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 7.10
HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev (2009) 5.24
Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer (2009) 5.11
MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem (2008) 4.69
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell (2009) 3.68
The perivascular niche regulates breast tumour dormancy. Nat Cell Biol (2013) 3.36
Exosome secretion: molecular mechanisms and roles in immune responses. Traffic (2011) 3.36
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta (2010) 3.33
MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab (2009) 3.30
Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One (2010) 3.23
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle (2009) 3.07
Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal (2008) 2.97
MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res (2009) 2.93
In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc (2010) 2.71
Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem (2009) 2.66
Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A (2013) 2.32
MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle (2010) 2.18
Isolation and characterization of RNA-containing exosomes. J Vis Exp (2012) 2.16
miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ (2010) 2.09
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03
Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics (2010) 1.97
Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J (2006) 1.93
Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer (2012) 1.92
MiR-210--micromanager of the hypoxia pathway. Trends Mol Med (2010) 1.90
Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. Nat Cell Biol (2012) 1.87
MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem (2010) 1.76
Tissue inhibitors of metalloproteinases. Genome Biol (2011) 1.62
Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res (1999) 1.56
miR-210: the master hypoxamir. Microcirculation (2012) 1.56
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem (2003) 1.52
Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Anticancer Res (2000) 1.45
Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther (2006) 1.44
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry (1991) 1.41
MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis (2013) 1.37
Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology (2011) 1.36
Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis. PLoS One (2013) 1.36
Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res (2005) 1.32
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 1.30
The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci (2008) 1.28
Negative regulation of Hif1a expression and TH17 differentiation by the hypoxia-regulated microRNA miR-210. Nat Immunol (2014) 1.27
A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol (2011) 1.26
Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis (2008) 1.24
Cytokine functions of TIMP-1. Cell Mol Life Sci (2013) 1.23
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer (1998) 1.12
TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein. Oncogene (2006) 1.09
Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer (2005) 1.04
Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res (2001) 1.02
Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med (2012) 1.01
TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS One (2012) 0.99
Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol (2005) 0.98
Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta (2009) 0.96
On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1α, and miR-210. Front Pharmacol (2012) 0.93
Prognostic significance of TIMP-1 in non-small cell lung cancer. Anticancer Res (2011) 0.93
Proteolytic factors in exosomes. Proteomics (2013) 0.90
Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci (2006) 0.90
Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res (2002) 0.87
Tissue inhibitor of metalloproteinase-1 promotes NIH3T3 fibroblast proliferation by activating p-Akt and cell cycle progression. Mol Cells (2011) 0.84
Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo (2003) 0.83
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α. Clin Exp Metastasis (2010) 0.81
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II. Arch Immunol Ther Exp (Warsz) (2011) 0.81
WSS25 inhibits Dicer, downregulating microRNA-210, which targets Ephrin-A3, to suppress human microvascular endothelial cell (HMEC-1) tube formation. Glycobiology (2013) 0.79
In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior. Virchows Arch (2013) 0.79
Full-length L1CAM and not its Δ2Δ27 splice variant promotes metastasis through induction of gelatinase expression. PLoS One (2011) 0.79